Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions

Christopher G. Goetz, Joanne Wuu, Michael P. McDermott, Charles Howard Adler, Stanley Fahn, Curt R. Freed, Robert A. Hauser, Warren C. Olanow, Ira Shoulson, P. K. Tandon, Karl Kieburtz, Sue Leurgans

Research output: Contribution to journalArticle

163 Citations (Scopus)

Abstract

Placebo-associated improvements have been previously documented in small series of Parkinson's disease (PD) patients. Using a strict definition of placebo-associated improvement, we examined rates and timing of placebo responses to identify patient- and study-based characteristics, predicting positive placebo response in several PD clinical trials. We collected individual patient data from the placebo groups of 11 medical and surgical treatment trials involving PD patients with differing PD severities and placebo-assignment likelihoods. We defined a positive placebo response as ≥50% improvement in total Unified Parkinson's Disease Rating Scale motor (UPDRSm) score or a decrease by ≥2 points on at least two UPDRSm items compared to baseline. We calculated positive placebo response rates at early (3-7 weeks), mid (8-18 weeks), and late (23-35 weeks) stages of follow-up. Odds ratios for patient- and study-based characteristics were obtained from a model fitted using generalized estimating equations. There were 858 patients on placebo who met inclusion criteria for analysis. Three studies involved patients without need of symptomatic treatment, two involved patients without motor fluctuations needing symptomatic treatment, and six (three medical and three surgical) involved patients with motor fluctuations. The overall placebo response rate was 16% (range: 0-55%). Patients with higher baseline UPDRSm scores and studies that focused on PD with motor fluctuations, surgical interventions, or those with a higher probability of placebo assignment showed increased odds of positive placebo response. Placebo responses were temporally distributed similarly during early, mid, and late phases of follow-up. Placebo-related improvements occur in most PD clinical trials and are similarly distributed across all 6 months of follow-up. Recognition of factors that impact placebo response rates should be incorporated into individual study designs for PD clinical trials.

Original languageEnglish (US)
Pages (from-to)690-699
Number of pages10
JournalMovement Disorders
Volume23
Issue number5
DOIs
StatePublished - Apr 15 2008

Fingerprint

Parkinson Disease
Placebos
Clinical Trials
Therapeutics
Odds Ratio

Keywords

  • Parkinson's disease
  • Placebo
  • Randomized clinical trials

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Placebo response in Parkinson's disease : Comparisons among 11 trials covering medical and surgical interventions. / Goetz, Christopher G.; Wuu, Joanne; McDermott, Michael P.; Adler, Charles Howard; Fahn, Stanley; Freed, Curt R.; Hauser, Robert A.; Olanow, Warren C.; Shoulson, Ira; Tandon, P. K.; Kieburtz, Karl; Leurgans, Sue.

In: Movement Disorders, Vol. 23, No. 5, 15.04.2008, p. 690-699.

Research output: Contribution to journalArticle

Goetz, CG, Wuu, J, McDermott, MP, Adler, CH, Fahn, S, Freed, CR, Hauser, RA, Olanow, WC, Shoulson, I, Tandon, PK, Kieburtz, K & Leurgans, S 2008, 'Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions', Movement Disorders, vol. 23, no. 5, pp. 690-699. https://doi.org/10.1002/mds.21894
Goetz, Christopher G. ; Wuu, Joanne ; McDermott, Michael P. ; Adler, Charles Howard ; Fahn, Stanley ; Freed, Curt R. ; Hauser, Robert A. ; Olanow, Warren C. ; Shoulson, Ira ; Tandon, P. K. ; Kieburtz, Karl ; Leurgans, Sue. / Placebo response in Parkinson's disease : Comparisons among 11 trials covering medical and surgical interventions. In: Movement Disorders. 2008 ; Vol. 23, No. 5. pp. 690-699.
@article{f5d8cc6469ce4eb1b945305ba19dc18e,
title = "Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions",
abstract = "Placebo-associated improvements have been previously documented in small series of Parkinson's disease (PD) patients. Using a strict definition of placebo-associated improvement, we examined rates and timing of placebo responses to identify patient- and study-based characteristics, predicting positive placebo response in several PD clinical trials. We collected individual patient data from the placebo groups of 11 medical and surgical treatment trials involving PD patients with differing PD severities and placebo-assignment likelihoods. We defined a positive placebo response as ≥50{\%} improvement in total Unified Parkinson's Disease Rating Scale motor (UPDRSm) score or a decrease by ≥2 points on at least two UPDRSm items compared to baseline. We calculated positive placebo response rates at early (3-7 weeks), mid (8-18 weeks), and late (23-35 weeks) stages of follow-up. Odds ratios for patient- and study-based characteristics were obtained from a model fitted using generalized estimating equations. There were 858 patients on placebo who met inclusion criteria for analysis. Three studies involved patients without need of symptomatic treatment, two involved patients without motor fluctuations needing symptomatic treatment, and six (three medical and three surgical) involved patients with motor fluctuations. The overall placebo response rate was 16{\%} (range: 0-55{\%}). Patients with higher baseline UPDRSm scores and studies that focused on PD with motor fluctuations, surgical interventions, or those with a higher probability of placebo assignment showed increased odds of positive placebo response. Placebo responses were temporally distributed similarly during early, mid, and late phases of follow-up. Placebo-related improvements occur in most PD clinical trials and are similarly distributed across all 6 months of follow-up. Recognition of factors that impact placebo response rates should be incorporated into individual study designs for PD clinical trials.",
keywords = "Parkinson's disease, Placebo, Randomized clinical trials",
author = "Goetz, {Christopher G.} and Joanne Wuu and McDermott, {Michael P.} and Adler, {Charles Howard} and Stanley Fahn and Freed, {Curt R.} and Hauser, {Robert A.} and Olanow, {Warren C.} and Ira Shoulson and Tandon, {P. K.} and Karl Kieburtz and Sue Leurgans",
year = "2008",
month = "4",
day = "15",
doi = "10.1002/mds.21894",
language = "English (US)",
volume = "23",
pages = "690--699",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Placebo response in Parkinson's disease

T2 - Comparisons among 11 trials covering medical and surgical interventions

AU - Goetz, Christopher G.

AU - Wuu, Joanne

AU - McDermott, Michael P.

AU - Adler, Charles Howard

AU - Fahn, Stanley

AU - Freed, Curt R.

AU - Hauser, Robert A.

AU - Olanow, Warren C.

AU - Shoulson, Ira

AU - Tandon, P. K.

AU - Kieburtz, Karl

AU - Leurgans, Sue

PY - 2008/4/15

Y1 - 2008/4/15

N2 - Placebo-associated improvements have been previously documented in small series of Parkinson's disease (PD) patients. Using a strict definition of placebo-associated improvement, we examined rates and timing of placebo responses to identify patient- and study-based characteristics, predicting positive placebo response in several PD clinical trials. We collected individual patient data from the placebo groups of 11 medical and surgical treatment trials involving PD patients with differing PD severities and placebo-assignment likelihoods. We defined a positive placebo response as ≥50% improvement in total Unified Parkinson's Disease Rating Scale motor (UPDRSm) score or a decrease by ≥2 points on at least two UPDRSm items compared to baseline. We calculated positive placebo response rates at early (3-7 weeks), mid (8-18 weeks), and late (23-35 weeks) stages of follow-up. Odds ratios for patient- and study-based characteristics were obtained from a model fitted using generalized estimating equations. There were 858 patients on placebo who met inclusion criteria for analysis. Three studies involved patients without need of symptomatic treatment, two involved patients without motor fluctuations needing symptomatic treatment, and six (three medical and three surgical) involved patients with motor fluctuations. The overall placebo response rate was 16% (range: 0-55%). Patients with higher baseline UPDRSm scores and studies that focused on PD with motor fluctuations, surgical interventions, or those with a higher probability of placebo assignment showed increased odds of positive placebo response. Placebo responses were temporally distributed similarly during early, mid, and late phases of follow-up. Placebo-related improvements occur in most PD clinical trials and are similarly distributed across all 6 months of follow-up. Recognition of factors that impact placebo response rates should be incorporated into individual study designs for PD clinical trials.

AB - Placebo-associated improvements have been previously documented in small series of Parkinson's disease (PD) patients. Using a strict definition of placebo-associated improvement, we examined rates and timing of placebo responses to identify patient- and study-based characteristics, predicting positive placebo response in several PD clinical trials. We collected individual patient data from the placebo groups of 11 medical and surgical treatment trials involving PD patients with differing PD severities and placebo-assignment likelihoods. We defined a positive placebo response as ≥50% improvement in total Unified Parkinson's Disease Rating Scale motor (UPDRSm) score or a decrease by ≥2 points on at least two UPDRSm items compared to baseline. We calculated positive placebo response rates at early (3-7 weeks), mid (8-18 weeks), and late (23-35 weeks) stages of follow-up. Odds ratios for patient- and study-based characteristics were obtained from a model fitted using generalized estimating equations. There were 858 patients on placebo who met inclusion criteria for analysis. Three studies involved patients without need of symptomatic treatment, two involved patients without motor fluctuations needing symptomatic treatment, and six (three medical and three surgical) involved patients with motor fluctuations. The overall placebo response rate was 16% (range: 0-55%). Patients with higher baseline UPDRSm scores and studies that focused on PD with motor fluctuations, surgical interventions, or those with a higher probability of placebo assignment showed increased odds of positive placebo response. Placebo responses were temporally distributed similarly during early, mid, and late phases of follow-up. Placebo-related improvements occur in most PD clinical trials and are similarly distributed across all 6 months of follow-up. Recognition of factors that impact placebo response rates should be incorporated into individual study designs for PD clinical trials.

KW - Parkinson's disease

KW - Placebo

KW - Randomized clinical trials

UR - http://www.scopus.com/inward/record.url?scp=44449093495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44449093495&partnerID=8YFLogxK

U2 - 10.1002/mds.21894

DO - 10.1002/mds.21894

M3 - Article

C2 - 18228568

AN - SCOPUS:44449093495

VL - 23

SP - 690

EP - 699

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 5

ER -